Higher showed no clear difference in mortality to hospital discharge compared with lower amino acid intake (low certainty).
It is very uncertain whether higher changes neurodevelopmental disability compared with lower amino acid intake (very low certainty).
It is very uncertain whether higher changes postnatal growth failure at discharge (weight < 10th centile) compared with lower amino acid intake (very low certainty).
It is very uncertain whether higher changes retinopathy of prematurity compared with lower amino acid intake (very low certainty).
Higher leads to higher abnormal blood urea nitrogen (various criteria) compared with lower amino acid intake (high certainty).
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in sepsis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).